Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced the appointment of Narinder Singh as Executive Vice President, Technical Operations. Mr. Singh is a proven biopharmaceutical executive with over two decades of deep technical, operational, and strategic leadership experience in end-to-end biopharmaceutical clinical development and commercialization, launch, and life cycle management for a variety of biopharmaceuticals such as biologics, biosimilars, complex generics, peptide vaccines and T-cell therapies.